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Abstract 
 
Background: Multiple reforms in South Africa to conserve resources including policies to 
enhance generic use such as compulsory generic substitution and co-payments. However, 
limited knowledge of their impact. Objective:  Determine utilisation and expenditure of 
different proton pump inhibitors (PPIs). Methodology: Retrospective drug utilisation study of 
a medical aid administrator in 2010. Results: Limited prescribing of single-sourced PPIs at 
21.5% total  prescriptions. Limited use of originator omeprazole and lansoprazole at 1.8% and 
1.4% of total prescriptions for the molecule. Generic prices 36% to 68% of the originator in 
2010. Patients received on average 2.91 PPI prescriptions during the year. Conclusion: 
Policies to enhance prescribing of generics appear working. Opportunities exist to further 
lower generic prices given low prices in some European countries. 
 
Background 
 
Medicines have made an appreciable contribution to improving health outcomes in recent 
years (1, 2). However, pharmaceutical expenditure is coming under increasing scrutiny 
worldwide (3, 4), rising by more than 50% in real terms during the past decade among OECD 
countries (5). As a result, expenditure on pharmaceuticals is now the largest, or equalling the 
largest, cost component in ambulatory care, and in some countries is up to 60% of total 
healthcare expenditure (3, 4, 6) . In addition in low and middle income countries, health care 
expenditure accounts for between 13 to 32% of total household expenditures with one in four 
poor households in low income countries incurring potentially catastrophic health care 
expenses when family members become ill (7). Typically, between 40% and 60% of 
households spend 100% of health care expenditure on medicines (7). The goal in all 
countries including Europe is to provide sustained universal access to healthcare including 
medicines (8-13).  
 
Different reforms and initiatives have been instigated across countries to conserve resources 
to fund new valued medicines as well as increased medicine volumes without increasing 
taxes, health insurance or out-of-pocket expenditures. This also includes increasing patient 
access to medicines where this is a concern. 
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Reforms and initiatives for established medicines include measures to increase the 
prescribing and dispensing of low cost generics versus originators. Measures include 
encouraging International non-proprietary name (INN) prescribing through multiple initiatives, 
e.g. UK; alternatively instigating compulsory INN prescribing apart from a limited number of 
cases as seen in Lithuania (4, 14, 15). Alternatively,  compulsory generic substitution and/ or 
making patients pay the difference in price between a generic and a more expensive 
originator in addition to any co-payment for the medicine dispensed (4, 16-19) . Other 
measures include enhancing the prescribing of multiple sourced (generic) medicines versus 
single-sourced medicines in a class where all the medicines in the class are seen as 
essentially therapeutically similar (4, 20). As a result, conserve resources without 
compromising care (4, 20-23). Pertinent classes include the proton pump inhibitors (PPIs), 
statins and the renin-angiotensin inhibitor drugs, which include both the angiotensin 
converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) (21, 23-30) . 
Savings can be substantial with prices of generics as low as 2 to 10% of pre-patent loss 
prices in some countries (15, 17, 24, 31). For instance, reimbursed expenditure for the PPIs 
and statins in the Netherlands fell by 58% and 14% respectively in 2010 vs. 2000 despite a 3 
and 3.8 fold increase respectively in utilisation. This was helped by multiple demand-side 
measures increasing the utilisation of generic PPIs at 2% of their pre-patent loss prices (24) . 
In Scotland, multiple demand-side measures resulted in reimbursed expenditure for the PPIs 
in 2010 56% below 2001 levels despite a 3 fold increase in utilisation (15) .  
 
South Africa is no different with generic prescribing and generic substitution targeted as 
possible mechanisms for cost containment.  South Africa implemented mandatory generic 
substitution in May 2003, making it a legal requirement according to the Medicines and 
Related Substances Act (Act 101 of 1965) (32) to inform patients of the availability of 
alternative generic medicines to allow them to make an informed choice. Alongside this, many 
medical aid schemes in South Africa, including the database used in this study, will only 
reimburse the cost of the generic product, and a co-payment is required if patients want the 
more expensive originator product.  Generic prescribing accounted for almost 50% of the 
market in volume and for a third of sales value (33) in 2005, up from 30% of the market in 
volume and 20% of sales value in 2004 (34). However, little is known about the current 
situation including the prices of generics versus originators in the various classes. We would 
though expect to see increased utilisation of generics in South Africa as more standard 
treatments become available as generics, especially with the introduction of mandatory 
generic substitution (35, 36). 
 
In South Africa, patients can also register certain chronic conditions with their medical 
insurance scheme and, if approved, can receive their medication under the chronic plan of the 
medical aid scheme.  This option prevents the medical aid benefits of patients being depleted 
due to the often high cost and monthly prescriptions for chronic conditions.  A chronic 
condition is defined as a condition for which treatment lasts for a period of at least three 
months.  The Council for Medical Schemes in South Africa publishes a Chronic Disease List 
(CDL), which specifies the mediation and treatment for the 25 chronic conditions that are 
compulsory for pharmaceutical benefit managers (PBMs) to cover (37).  Although PPIs are 
not explicitly included, patients can apply for their condition to be registered as chronic at the 
discretion of the specific medical aid scheme that they belong to and this could include the 
prescribing of PPIs. 
 
PPIs are one of the most frequently prescribed classes of medicines worldwide due to their 
effectiveness and limited side-effects across a range of upper gastrointestinal disorders (38-
40).  However, there are growing concerns with the overprescribing of PPIs across countries 
(38). There are also concerns with the side-effects of long-term use, that is an increase in 
infection rates including hospital and community-acquired pneumonia as well as osteoporosis, 
which can result in increased fracture rates (41-45). Other authors though have not seen this 
association (46). 
 
The primary aim of this study is to investigate the utilisation of the different PPIs, including 
both multiple sourced (generic) and patented (originator) PPIs, and their associated costs in 
South Africa to provide future guidance. The typical number of prescriptions prescribed in a 
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year will also be investigated given the increasing safety concerns with long-term chronic use 
of PPIs. 
 
Methodology 
 
A retrospective drug utilization study was conducted on a prescription database of a private 
medical aid administrator in South Africa.  The health care system in South Africa consists of 
a public sector and a private sector. Health care in the public sector is provided by the 
national government for patients who are unable to afford a private medical aid, which 
currently accounts for over 89% of the population(47). The private sector is funded by the 
income from patients, with people belong to one of the available private medical aid 
(insurance) schemes. These medical insurance schemes have electronic databases enabling 
accurate research to be conducted, with most medical insurance schemes administered by an 
administrator overseeing several individual medical aid schemes. This compares to the public 
sector where there is limited access to utilisation and expenditure data, and available data is 
not routinely collected electronically (48). Patient dosing data is also not accurately recorded 
electronically in the public system.  
 
The database used in this study is from one of the administrators in South Africa and is 
considered representative of prescribing in the private health care sector since it includes 
patients from all the different provinces. 
 
Data from the prescription database covered the year 2010, and included all medications 
prescribed, procedures and devices (a total of 2,126,264 records).  Each medication record 
contained information on the age and gender of the patient, with a unique number to identify 
each patient, the date of the prescription, detailed information on the dispensed drug (name, 
package size, formulation, strength and quantity), price and various reimbursement variables.  
As mentioned, only generic prices are reimbursed with patients covering the additional costs 
themselves if they wish a more expensive originator. The database contains details of the 
reimbursed costs as well as co-payment details. Sales of OTC PPIs that are not reimbursed 
by the medical insurance schemes are not included in the database. However, details of OTC 
products are included if the cost of OTC products are included in individual medical aid 
insurance schemes.  This is similar to the situation in Europe where typically expenditure on 
OTC medicines are not reimbursed; consequently, not included in health authority databases 
(20).  
 
The Anatomical Therapeutic Chemical (ATC) Classification System (49), Monthly Index of 
Medical Specialities (MIMS) (50) and the South African Medicines Formulary (51) were used 
to identify the medicines that were prescribed.  For the purpose of this study, medicine items 
(prescriptions) were principally extracted and analysed (MIMS category 12.4.4) as this 
contains all formulations (50). A sub-analysis was also performed on cost/ DDD (defined daily 
dose) (49) for the various oral formulations, excluding IV and infusion powder formulations, to 
compare price differences between oral generic and originator PPIs in 2010. This would also 
enable comparisons with the price differentials seen between originator and generic PPIs 
among European countries to provide suggestions for the future if pertinent. This builds on 
comments in the introduction. 
 
Microsoft Access
®
 and Excel
®
 were used to analyse the data.  Basic descriptive statistics 
were calculated.  2QH(XUR¼ZDVHTXDOWR=$59.38 (South African Rand), one US 
Dollar ($1.00) was equal to ZAR7.64 and one British Pound (£1.00) was equal to ZAR11.48 at 
the time of the study (30 June 2010). 
 
Results 
 
A total of 20,537 PPIs were prescribed to 7,060 patients over the year at a total cost of 
ZAR3,985,845.45 including any patient co-payments.  Patients received on average 2.91 (SD 
= 3.03) PPI prescriptions during the year (range: 1 to 28 prescriptions). The average age of 
patients was 44.10 (SD = 16.31) years (range:  0 to 96 years).  Half of the patients (50.88%) 
were female.  Only 18.6% of the prescriptions were claimed on the chronic option of the 
different medical aid schemes. Approximately70% of PPI prescriptions (69.1%) were 
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dispensed in quantities of 28 or 30 dosage units (tablets or capsules) per month, or multiples 
thereof.  A further 9.8% of prescriptions for were dispensed in doses of 7, 14 or 15 units per 
month, with different units for the remainder. Typically in South Africa, repeat prescriptions 
are only dispensed for a period of one month.  Consequently, if a patient receives a repeat for 
three months, the patient will have to come into the pharmacy three times to collect their 
supply for that specific month. This will reflect as three different prescriptions for the same 
patient in the study. 
 
x Prescribing of PPIs 
 
All five PPIs were available in South Africa in 2010.  Omeprazole was the most prescribed 
PPI (Table 1), accounting for half of all PPIs prescribed (50.8%), followed by esomeprazole 
(19.8%) and lansoprazole (18%). Overall, single-sourced PPIs accounted for 21.5% of total 
PPIs in 2010 (Table 1). 
 
TABLE 1 ± Prescribing frequency (items prescribed) of the PPIs by gender in 2010 
 
ACTIVE 
INGREDIENTS 
NUMBER OF 
PRESCRIPTIONS GENDERS COMBINED 
Female Male NUMBER % 
Esomeprazole* 19.3 20.4 4 073 19.8 
Lansoprazole 17.4 18.7 3 705 18.0 
Omeprazole 51.4 50.1 10 429 50.8 
Pantoprazole 10.3 9 1 988 9.7 
Rabeprazole* 1.6 1.8 342 1.7 
TOTAL 100 100 20 537 100 
NB: *=single-sourced medicines, i.e. no generics available 
 
Patients received on average 1.21 (SD = 0.49) different PPI active ingredients over the year 
from the average of 2.91 PPI prescriptions per year.  Most patients (82%) were only 
prescribed one PPI active ingredient during the year, 15% two different PPI active ingredients, 
2.75% three and 0.25% four different active ingredients. 
 
Eight different trade names (brand names) of omeprazole were prescribed with one generic 
product (Altosec£) accounting for 56% of all omeprazole prescriptions (Table A1).  The 
originator product (Losec£) accounted for 1.8% of total omeprazole prescriptions.  Nine trade 
names of lansoprazole were prescribed, with the originator accounting for 1.4% of prescribing 
frequency (Table A1). There were similar low prescribing rates for oral originator omeprazole 
and lansoprazole when prescriptions were converted into DDDs at 0.9% and 0.8% 
respectively (Table A2). There were higher rates for originator pantoprazole at 16.7%.  
 
The average cost/prescription for lansoprazole and omeprazole, which was principally the 
generic versions, was ZAR154.42 and ZAR157.76 respectively vs. ZAR308.97 for 
esomeprazole (Figure 1). 
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Figure 1 ± Average cost/ prescription for each PPI in 2010 (South African Rand - ZAR) 
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The high frequency of prescribing generic vs. originator lansoprazole and generic vs. 
originator omeprazole (98% to 99% by prescription and DDD) at lower costs (Table 2) 
resulted in lower costs versus frequency of prescribing for these two active ingredients 
compared with patented (single-sourced) esomeprazole (Figure 2). 
 
Table 2 ± Cost (Rand)/ DDD for different oral PPIs where generic versions exist 
 
PPI Cost/ DDD % of originator % Reduction
Lanzoprazole
Originator 16.95
Total Generics 6.14 36.3 63.7
Omeprazole 
Originator 13.26
Total Generics 5.43 41.0 59.0
Pantoprazole
Originator 13.86
Total Generics 8.91 67.6 32.4  
 
NB Controloc£ and Pantoloc£ have both been included as originator products for pantoprazole 
 
Figure 2 - % prescribing frequency (% of total prescriptions) versus costs (% of total costs) for 
the 5 PPIs in 2010. Frequency in terms of overall items dispensed 
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Figure 3 shows a comparison of the average cost of the different name products (originator 
and branded generics) prescribed for lansoprazole, omeprazole and pantoprazole.  For all 
three PPIs, the originator products were more expensive than the average cost of the different 
branded generics. 
 
Figure 3 ± Comparison of average costs per prescription (Rand) of originator (yellow) versus 
generic (blue) products for lansoprazole, omeprazole and pantoprazole  
 
 
NB: *Controloc£ and Pantoloc£ are identical originator molecules of pantoprazole but branded 
differently, therefore they are both again indicated as originator products. 
 
DISCUSSION 
 
There are a number of different implications and conclusions that can be drawn from these 
results.  
 
Firstly, the policies including mandatory generic substitution to enhance the prescribing of 
generic vs originator PPIs appear to be working well in South Africa with the utilisation of 
generic omeprazole and lansoprazole at 98 to 99% of total utilisation for their respective 
molecules (DDD basis). There were similar findings with the statins with high utilisation of 
generic statins versus originators in South Africa in recent years (52). These results mirror the 
very high rates of utilisation of generic versus originator omeprazole the Netherlands (94% of 
total omeprazole on a defined daily dose ± DDD - basis) and the UK (98% on a DDD basis) 
(15, 24). This was achieved in both countries through multiple demand-side measures 
including preferential pricing policies with financial incentives (Netherlands) and encouraging 
INN prescribing (UK (15, 24) . However, we accept further studies are needed before 
definitive statements can be made about the extent of generic utilisation in recent years in 
South Africa. 
 
Policies to encourage the prescribing of lower costs generic versus single-sourced PPIs also 
appear to be working in South Africa with low utilisation of esomeprazole (19.8% of total 
prescriptions) versus omeprazole, lansoprazole and pantoprazole combined (78.5%) (Table 
1). Similar high rates of prescribing of generic PPIs versus esomeprazole were seen in 
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England, Germany, Scotland and Sweden, e.g. esomeprazole was only 14% of total PPIs in 
Sweden in 2007 (DDD basis), 13% in Germany, 6.8% in Scotland in 2007 (6.3% in 2010) and 
5.9% in England in 2007 with their multiple demand-side measures including reference pricing 
in a class, e.g. Germany,  to encourage the prescribing of low cost PPIs (15, 20). This 
compares with 23% in France, 31% in Ireland and 46% in Norway in 2007 with few demand-
side measures to counteract the influence of pharmaceutical companies (20). However, there 
is the potential to lower the utilisation of single-sourced PPIs in South Africa to further 
conserve resources based on the situation in the UK. 
 
These figures suggest that there appears to be no problems with branded generic PPIs in 
South Africa. This mirrors the situation in Europe (4, 15, 17, 24) . However, we acknowledge 
that we cannot say this with complete confidence as we have not undertaken specific studies 
comparing the outcomes of different branded generic PPIs with the respective originators in 
South Africa. However, our findings suggest there should be no problems in routine clinical 
practice. 
 
The chronic prescribing of PPIs does not appear currently to be an issue in South Africa with 
an average of 2.91 prescriptions per patient (typically 14 or 28 days ± Table A1) during the 
year. Again though, we cannot say this with certainty without looking at individual patients and 
individual PPIs. This will be the subject of further research given the increasing patient safety 
concerns with chronic prescribing of PPIs discussed earlier.  
 
However, there appears currently to be relatively high prices for generic PPIs in South Africa, 
i.e. between 68% to 36% of the originator price which corresponds to a 32% to 64% price 
reduction on a cost/ DDD basis (Table 2). Lower prices though were seen for some generic 
PPIs, e.g. Nozer with a 79% price reduction (Table A2). This compares with appreciably lower 
prices in the Netherlands, Scotland and Sweden where generic PPIs can be as low as 2% to 
10% of pre-patent loss prices, i.e. 90% to 98% price reduction, despite strict bioequivalence 
criteria (15, 17, 24) . In addition, population size does not appear to be a barrier to obtaining 
low prices for generics as seen in Lithuania and the Republic of Srpska (14, 53). One possible 
reason for the high prices for genHULFVLQ6RXWK$IULFDFRXOGEHWKDWWKH\DUHµEUDQGHG
JHQHULFV¶FRPSDUHGIRULQVWDQFHZLWKKLJK,11SUHVFULELQJUDWHVLQWKH8.(15). However, this 
cannot be the RQO\H[SODQDWLRQDVWKHUHDUHµEUDQGHGJHQHULFV¶LQ6ZHGHQ(17, 54).  
 
Potential ways forward for South Africa to achieve lower prices for generics could include 
either instigating a prescriptive pricing policy for generics as seen in Austria (60% below pre-
patent loss prices by the time the third generic is launched), France (55% below initially) or 
Norway (maximum of 85% below pre-patent loss prices for high volume generics); 
alternatively instigating aggressive market forces (54). Aggressive market forces could 
include increased transparency in the pricing of generics as seen in the UK with high INN 
prescribing rates coupled with regular requests for companies to provide data on the cost of 
producing generics as well as any rebates or discounts given to wholesalers or pharmacists 
to preferentially dispense a particular generic (15).  Alternatively, instigating tendering 
systems as seen in the Netherlands and Sweden (24, 54). In Sweden, there are now monthly 
auctions whereby the manufacturer that wins the bid for their particular generic is guaranteed 
an appreciable percentage of prescriptions the following month (54). These are 
considerations for the future as the healthcare market in South Africa evolves. 
 
There can also potentially be patient confusion if different branded generics each with 
different names are dispensed each time, especially with the wide variety of branded generic 
names currently available in South Africa (Table A1). This happens in Sweden (17, 54)   if 
patients do not receive adequate information about their medicines (17, 55). As a result, 
potentially leading to either duplication of medicines; alternatively, patients not taking their 
prescribed treatments as directed; consequently, not gaining the most benefit from their 
medication (56). These scenarios are exacerbated if pharmacists lack training on how to 
handle concerns with substitution and/ or do not receive adequate payment for providing 
relevant information to patients potentially limiting the time spent with them (31, 55). INN 
prescribing, apart from a limited number of well-known situations, is one way to address this 
as well as obtain low prices for generics especially with increased transparency in the pricing 
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of generics (15). This has worked well in the UK with very high INN prescribing rates of 98 to 
99% across a range of molecules (15). 
 
We accept that the limitations of the study include the fact that was no clinical information or 
diagnoses available in the database, and that only patients served by the private health care 
sector in South Africa were included in the study. However, we believe our findings are still 
valid and provide guidance to the authorities in South Africa in the future for the reasons we 
have documented. 
 
CONCLUSION 
 
The authors have shown that multiple demand-side reforms in South Africa have appreciably 
increased the prescribing of generics versus originators and single-sourced products in a 
class. However, additional measures are needed to further reduce the prescribing of single-
sourced PPIs to levels seen in the UK. The reforms have also led to prices of generic PPIs at 
36% to 68% of originator prices in 2010. Additional measures are needed to further lower 
generic prices to 10% or lower of originator prices to mirror the situation seen among some 
Western European countries with their aggressive generic pricing policies. It is hoped the 
findings and suggestions from this study will provide guidance to the authorities in South 
Africa regarding potential future measures they could consider to further improve prescribing 
efficiency. 
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Executive Summary 
 
x There have been multiple reforms in South Africa in recent years to encourage the 
prescribing of generics. This includes mandatory generic substitution and many medical 
aid schemes in South Africa only reimbursing the cost of the generic product 
x However, there are concerns with the long-term use of proton pump inhibitors (PPIs). In 
addition, limited knowledge of their utilisation patterns and expenditure in South Africa 
x Omeprazole was the most prescribed PPI, accounting for half of all PPIs prescribed 
(51%), followed by esomeprazole (20%) and lansoprazole (18%). Overall, patented 
(single-sourced) PPIs accounted for only 21.5% of total PPIs in 2010, which is 
comparable to Western European countries with multiple demand-side measures to 
reduce the prescribing of patented PPIs  
x Low utilisation of generic versus originator PPIs, with originator omeprazole accounting 
for only 1.8% of total omeprazole prescriptions and originator lansoprazole for only 1.4% 
of total lansoprazole prescriptions. This suggests policies to enhance the prescribing of 
generics in South Africa appear to be working 
x Patients received on average 1.21 different PPI active ingredients over the year and an 
average of 2.91 PPI prescriptions per year.  This suggests that chronic prescribing of 
PPIs does not appear currently to be an issue in South Africa. 
x There appears to be relatively high prices for generic PPIs in South Africa, i.e. between 
68% to 36% of the originator priceZKLFKFRXOGEHGXHWRµEUDQGHGJHQHULFV¶ This 
compares to low prices that have been achieved for generic PPIs in some European 
countries at between 2% to 10% of pre-patent loss prices, which provides a goal for 
South Africa in the future. 
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Table A1 ± Individual prescription data and costs for the PPIs in 2010 
 
ACTIVE 
INGREDIENT TRADE NAME 
STRENGTH AND PACK 
SIZE NUMBER TOTAL COST TOTAL 
Esomeprazole  
Nexiam£ 20mg, Tablets (14) 153   26867.54   
  20mg, Tablets (28) 504   156058.06   
  40mg, Tablets (14) 925   131339.68   
  40mg, Tablets (28) 1156   444914.19   
  
Intravenous 40mg, 
Injections (5) 1335 4073 499263.96 1258443.43 
Total     4073   1258443.43 
Lansoprazole  
Adco-Roznal 30mg, Capsules (28) 14 14 3407.41 3407.41 
Aspen-Lansoprazole£ 15mg, Capsules (30) 51   7600.77   
  15mg, Capsules (7) 22   1436.66   
  30mg, Capsules (30) 86   16786.08   
  OTC 15mg, Capsules (7) 30 189 1788.57 27612.08 
Gastrid£ 15mg, Capsules (30) 2 2 321.04 321.04 
Lancap£ 15mg, Capsules (30) 378   36283.86   
  30mg, Capsules (30) 1506 1884 202892.58 239176.44 
Lansoloc£ 15mg, Capsules (30) 292   48771.57   
  30mg, Capsules (30) 919   201403.64   
  OTC 15mg, Capsules (7) 228 1439 13375.15 263550.36 
Lansoprazole-Winthrop£ 15mg, Capsules (28) 9   1218.84   
  30mg, Capsules (28) 99 108 19098.16 20317.00 
Lanzor£ 15mg, Capsules (28) 15   2984.86   
  30mg, Capsules (14) 6   1160.72   
  30mg, Capsules (28) 18   9289.49   
  HB 15mg, Capsules (7) 14 53 918.25 14353.32 
Ran-Lansoprazole£ 15mg, Capsules (28) 5   662.74   
  30mg, Capsules (28) 2 7 308.54 971.28 
Simayla Lansoprazole£ 15mg, Capsules (28) 3   695.78   
  30mg, Capsules (28) 6 9 1717.28 2413.06 
Total     3705   572121.99 
Omeprazole  
Adco-Omeprazole£ 20mg, Capsules (28) 16   2144.64   
  20mg, Capsules (30) 709 725 114176.30 116320.94 
Altosec£ 10mg, Capsules (28) 217   31612.31   
  20mg, Capsules (28) 5623 5840 890508.07 922120.38 
DRL-Omeprazole£ 10mg, Capsules (30) 7   1018.37   
  20mg, Capsules (30) 290   35169.21   
  40mg, Capsules (30) 2 297 672.22 36859.80 
Lokit£ 20mg, Capsules (30) 903 903 141511.17 141511.17 
Losec£ 
Infusion powder 40mg, 
Injection (1) 39   20800.82   
  MUPS 10mg, Tab (28) 102   18822.53   
  MUPS 20mg, Tab (14) 26   3976.44   
  MUPS 20mg, Tab (28) 15   6420.97   
  MUPS 40mg, Tab (14) 1 183 483.42 50504.18 
Nozer£ 20mg, Capsules (28) 119   12042.72   
  20mg, Capsules (30) 131 250 8401.64 20444.36 
Omez£ 10mg, Capsules (30) 75   10643.40   
  20mg, Capsules (30) 1357   206216.39   
  40mg, Capsules (14) 64   10833.29   
  40mg, Capsules (28) 84 1580 26257.65 253950.73 
Sandoz Omeprazole£ 20mg, Capsules (30) 649 649 102506.07 102506.07 
Total     10427   1644217.63 
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Pantoprazole ** 
Topzole£ 20mg, ECT(28) 393   74897.46   
  40mg, ECT (28) 441 834 104805.11 179702.57 
Controloc£ 20mg, ECT (28) 43   10794.71   
  40mg, ECT (14) 4   1073.28   
  40mg, ECT (28) 11 58 3732.23 15600.22 
Pantocid£ 40mg, ECT (30) 154   20286.19   
  40mg/10ml Injections (5) 661 815 142891.65 163177.84 
Pantoloc£ 20mg, ECT (28) 80   17065.53   
  40mg, ECT (14) 51   5957.75   
  40mg, ECT (28) 51   19979.19   
  
Intravenous 40mg, 
Injections (5) 85 267 25980.93 68983.40 
Pentoz£ 20mg, ECT (30) 10   1530.91   
  40mg, ECT (30) 4 14 1155.92 2686.83 
Total     1988   430150.86 
Rabeprazole  
Pariet£ 10mg, Tablets (28) 97   14135.00   
  20mg, Tablets (14) 16   1979.33   
  20mg, Tablets (28) 229 342 64797.21 80911.54 
Total     342   80911.54 
TOTAL     20537   3985845.45   
 
* Originator products are indicated in yellow in the table. 
** Controloc£ and Pantoloc£ are identical originator molecules of pantoprazole but with 
different brand names. Consequently, they are both indicated as originator products. 
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Table A2 ± DDDs and expenditure/ DDD for generic and oral PPIs in 2010 
 
PPI DDD Exp/ DDD % of originator % Reduction
Lanzoprazole
Lanzor (Originator) 210
84
504
49 16.95
Total Originator 847 16.95
Adco-Roznal 392 8.69 51.3 48.7
Aspen 765
77
2580
105
Total Aspen 3527 7.83 46.2 53.8
Gastrid 30 10.70 63.1 36.9
Lancap 5670
45180
Total Lancap 50850 4.70 27.8 72.2
Lansoloc 4380
27570
798
Total Lansoloc 32748 8.05 47.5 52.5
Lansoprazole - Win 126
2772
Total Lansoprazole-Win 2898 7.01 41.4 58.6
Ran-Lansop 70
56
Total Ran-Lansop 126 7.71 45.5 54.5
Simayla Lan 42
168
Total Simayla Lan 210 11.49 67.8 32.2
Total generic 90781 6.14 36.3 63.7
Omeprazole 
Losec (originator) 1428
364
420
28
Total Originator 2240 13.26
Adco Omp 448
21270
Total Adco Omp 21718 5.36 40.4 59.6
Altosec 3038
157444
Total Altosec 160482 5.75 43.3 56.7
DRL Omp 105
8700
120
Total DRL Omp 8925 4.13 31.1 68.9
Lokit 27090 5.22 39.4 60.6
Nozer 3332
3930
Total Nozer 7262 2.82 21.2 78.8
Omez 1125
40710
1792
4704
Total Omez 48331 5.25 39.6 60.4
Sandoz Omep 19470 5.26 39.7 60.3
Total generic 293278 5.43 41.0 59.0
Pantoprazole 
Pantoloc (originator) 1120
714
1428
3262 13.18
Controloc (originator) 602
56
308
966 16.15
Total Originator 4228 13.86
Topzole 5502
12348
Total Topzole 17850 10.07 72.6 27.4
Pantocid 4620 4.39 31.7 27.3
Pentoz 150
120
Total Pentoz 270 9.95 71.8 28.2
Total generic 22740 8.91 67.6 32.4  
 
